timothy sykes logo
ABUS Jumps As Arbutus Biopharma Launches $230M Tender Offer Thumbnail
G Google News

ABUS Jumps As Arbutus Biopharma Launches $230M Tender Offer

MATT MONACO•UPDATED AUG. 22, 2026, 10:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Arbutus Biopharma Corporation stocks have been trading up by 10.86 percent amid optimism over its advancing hepatitis B pipeline.

What Traders Need To Know

  • A modified Dutch auction will repurchase up to $230M of common stock at $5.00–$5.75, fully funded from existing cash.
  • The tender offer, fueled by a $950M global patent settlement with Moderna, pushed shares roughly 9–10% higher in premarket and intraday trade after the announcement.
  • Q2 2026 revenue came in at $1.0M, about 43% above the $0.7M FactSet estimate, adding a small but positive data point.
  • Management has already received $178M from the Moderna deal and expects further value via a 16% Genevant stake.
  • The company aligned with the FDA on a Phase 2b trial and secured Fast Track status for hepatitis B RNAi therapy imdusiran (AB-729), while pursuing LNP patent lawsuits against Pfizer/BioNTech.

Candlestick Chart

Weekly Update Aug 17 – Aug 21, 2026: On Saturday, August 22, 2026 Arbutus Biopharma Corporation stock [NASDAQ: ABUS] is trending up by 10.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Arbutus Biopharma (ABUS) has shifted from a capital-constrained clinical biotech to an IP-rich, cash-heavy platform following the $950M Moderna settlement, reflected in a pristine balance sheet (no debt, current ratio >80x, working capital ~$271M). Reported margins and ROE/ROA are distorted by settlement accounting, but core operations remain loss-making (Q2’26 net loss ~$5.1M on $1.0M revenue, negative FCF ~$6.0M). Enterprise value of ~$939M and P/S ~5.2 embed meaningful expectations for continued IP monetization beyond HBV.

On the weekly tape, ABUS shows an aggressive trend change: a quick move from $4.71 to $5.29 with successive higher closes and tight intraday ranges, confirming strong demand into the Dutch auction announcement. Intraday 5‑minute action shows heavy volume clustering between $4.90–$5.10, establishing a clear near-term value area. The dominant trend is now up; $5.00 is the key actionable level—buy-the-dip support and stop-loss trigger—while $5.75 (tender cap) defines near-term upside anchor and likely supply zone.

The modified Dutch auction for up to $230M at $5.00–$5.75, funded entirely with cash, is a powerful capital allocation signal and creates a hard valuation floor versus typical small-cap biotech peers. Relative to Healthcare and Biotech benchmarks, ABUS offers superior balance sheet strength and non-dilutive IP optionality (ongoing Pfizer/BioNTech LNP suits, Genevant stake) but higher litigation and program concentration risk. I see favorable risk/reward with technical support at $5.00, resistance at $5.75, and a 6–12 month upside target of $7.00.

More Breaking News

Quick Financial Overview

Arbutus Biopharma Corporation has shifted its financial profile with the $950M patent settlement from Moderna. The balance sheet now shows $92.6M in cash, cash equivalents, and short-term investments and working capital of about $270.5M, giving ABUS unusual liquidity for a small-cap biotech. With total liabilities of only $15.3M and no long-term debt, the company’s financial strength ratios look extreme, including a current ratio above 80, though traders should remember these are boosted by one-off legal proceeds.

On the income side, ABUS is still loss-making. Q2 2026 total revenue was $1.0M against operating expenses of $7.0M, driving a net loss of $5.1M and negative operating cash flow of $6.0M. The reported P/E near 6.0 and very high margins mostly reflect settlement-related accounting, not a mature, recurring earnings base, so traders should be careful not to treat ABUS like a steady cash cow.

Price action confirms how the market is re-pricing this new story. On the weekly tape, ABUS climbed from around $4.71 to about $5.29 into the tender news window, with clear expansion off the $4.70s base. Intraday, the 5-minute candle shows a surge from roughly $5.20 to a $5.45 high before settling near $5.21, signaling a strong initial spike and then some digestion right around the lower end of the tender range.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”